Triple combination therapy for clinically nonmetastatic super-high-risk prostate cancer

IntroductionPatients with nonmetastatic but exceptionally high-risk prostate cancer are liable to have biochemical failure and may even die. Triple combination therapy, which consists of surgery, radiotherapy, and androgen-deprivation therapy, as first-line treatment, may control the disease for a l...

Full description

Saved in:
Bibliographic Details
Published in:IJU case reports 2022, Vol.5 (4), p.273-275
Main Authors: Yoshimura, Koji, Muraoka, Kei, Fukasawa, Michiko, Fukushima, Mika, Kumagai, Masatoshi, Yabusaki, Ryo, Ueda, Masakatsu, Shiraishi, Yusuke, Imamura, Masaaki
Format: Report
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:IntroductionPatients with nonmetastatic but exceptionally high-risk prostate cancer are liable to have biochemical failure and may even die. Triple combination therapy, which consists of surgery, radiotherapy, and androgen-deprivation therapy, as first-line treatment, may control the disease for a long period. Case presentationWe treated a patient with super-high-risk, nonmetastatic prostate cancer, with triple combination therapy. He was biochemical relapse free at 60 months after the initiation of treatment. ConclusionTriple combination therapy may be an option for super-high-risk, nonmetastatic prostate cancer.
ISSN:2577-171X
DOI:10.1002/iju5.12457